Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.

@article{Baldwin2003VacciniaexpressedHP,
  title={Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.},
  author={Peter J. W. Baldwin and Sjoerd H van der Burg and Christopher M. Boswell and Rienk Offringa and Julian K Hickling and Jennifer Dobson and John St Clair Roberts and John A. Latimer and Robin P Moseley and Nicholas Coleman and Margaret Stanley and Jane Carolyn Sterling},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 14},
  pages={5205-13}
}
PURPOSE Anogenital intraepithelial neoplasia is a chronic disorder associated with infection by high-risk human papillomavirus (HPV) types. It is frequently multifocal and recurrence after conventional treatment is high. Boosting HPV-specific cell-mediated immune responses may reduce progression to carcinoma and could lead to disease clearance. We have tested the safety, immunogenicity, and efficacy of a recombinant vaccinia candidate vaccine (TA-HPV) in women with anogenital intraepithelial… CONTINUE READING